Recommendations for raloxifene use in daily clinical practice in the Swiss setting
2012
Background/aim
Raloxifene is the first selective estrogen receptor modulator that has been approved for the treatment and prevention of osteoporosis in postmenopausal women in Europe and in the US. Although raloxifene reduces the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer, it is approved in that indication in the US but not in the EU. The aim was to characterize the clinical profiles of postmenopausal women expected to benefit most from therapy with raloxifene based on published scientific evidence to date.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
62
References
10
Citations
NaN
KQI